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Abstract
The Optimising treatment for acute MAlnutrition (OptiMA) strategy trains mothers to use mid upper arm circumference (MUAC) bracelets for
screening and targets treatment to children with MUAC < 125 mm or oedema with one therapeutic food at a gradually reduced dose. This
study seeks to determine whether OptiMA conforms to SPHERE standards (recovery rate > 75 %). A single-arm proof-of-concept trial was
conducted in 2017 in Yako district, Burkina Faso including children aged 6–59 months in outpatient health centres with MUAC < 125 mm or
oedema. Outcomes were stratified by MUAC category at admission. Multivariate survival analysis was carried out to identify variables pre-
dictive of recovery. Among 4958 children included, 824 (16·6 %) were admitted with MUAC < 115 mm or oedema, 1070 (21·6 %) with MUAC
115–119 mm and 3064 (61·8 %) with MUAC 120–124 mm. The new dosage was correctly implemented at all visits for 75·9 % of children.
Global recovery was 86·3 (95 % CI 85·4, 87·2) % and 70·5 (95 % CI 67·5, 73·5) % for children admitted with MUAC < 115 mm or oedema.
Average therapeutic food consumption was 60·8 sachets per child treated. Recovery was positively associated with mothers trained to use
MUAC prior to child’s admission (adjusted hazard ratio 1·09; 95 % CI 1·01, 1·19). OptiMA was successfully implemented at the scale of an
entire district under ‘real-life’ conditions. Programme outcomes exceeded SPHERE standards, but further study is needed to determine if
increasing therapeutic food dosages for the most severely malnourished will improve recovery.
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Acute malnutrition is a major public health problem, affecting
49·5 million children worldwide each year and contributing to
nearly half of all annual childhood deaths(1,2). One quarter of
all acutely malnourished children are in Africa with the largest
number, 5·1 million, in West Africa(2). In this region, the burden
of acutemalnutrition overlapswith the highest rates of childmor-
tality(2). Progress in reducing acute malnutrition needs to
accelerate in the region if it is to meet WHO Global Nutrition
Targets by 2025(3).
Although acute malnutrition is a continuum condition, it is
arbitrarily divided into moderate (MAM) and severe (SAM) cat-
egories defined by mid upper arm circumference (MUAC) or
weight-for-height Z-score (WHZ). MAM (MUAC 115–124 mm
or WHZ between –2 and –3) and SAM (MUAC< 115 mm or
Abbreviations: AF, attributable fraction; MAM, moderate acute malnutrition; MUAC, mid upper arm circumference; OptiMA, Optimising treatment for acute
Malnutrition; RUTF, ready-to-use therapeutic food; SAM, severe acute malnutrition; WHZ, weight-for-height Z-score.
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WHZ <–3 or oedema) are managed separately, with pro-
grammes overseen by different UN agencies, and using different
protocols and products (ready-to-use supplementary food or
fortified-blended flours for MAM and ready-to-use therapeutic
food (RUTF) for SAM). Such separation complicates delivery
of care, contributes to low coverage and creates confusion
among caregivers(4).
Confusion is further exacerbated by a complicated case
definition using MUAC and WHZ to determine programme
eligibility, even though WHZ does not offer a clear advantage
over MUAC for identifying children at near-term risk of death(5).
MUAC-only programming is expanding as evidence accumu-
lates that weight gain and MUAC gain track each other and
that the trajectory of weight and MUAC gain is maximal during
the first 2–3 weeks of treatment(6–8). MUAC is therefore
becoming a stand-alone practical tool for all phases of nutrition
programming: screening, admission, monitoring recovery and
determining discharge.
In addition to the tangle of agencies and case definitions, SAM
and MAM programmes are chronically underfunded with only
25 % of SAM cases treated globally in 2016 and 16 % of
MAM cases reached by the World Food Program in 2017(9,10).
An optimised allocation of resources is therefore needed. A
programme integrating SAM and MAM treatment in a single
MUAC-based protocol using only RUTF showed the cost of
RUTF for integrated treatment to be less than half that for
standard SAM management(11). Other studies found that
identification and treatment of children earlier in the wasting
process led to fewer hospitalisations and that inpatient
care was shown to be twice as costly as outpatient SAM
management(12,13). Furthermore, the treatment of MAM has been
shown to be cost-effective in reducing mortality risk by more
than 10 %(14).
We piloted a new MUAC-based and oedema approach
for treating acute malnutrition in Burkina Faso with a
single-arm proof-of-concept trial called Optimising treatment
for acute MAlnutrition (OptiMA). OptiMA made three strategic
changes to the current Burkina Faso National Nutrition
protocol(15): screening for acute malnutrition was task-shifted
to caretakers via community-based training in the use of
MUAC bracelets; the case definition for acute malnutrition
was modified to MUAC < 125 mm and/or oedema and only
one product was used for treatment (RUTF) at a gradually
reduced dose based on a child’s weight and MUAC status.
We hypothesised that the OptiMA protocol was at least as
effective as the national nutrition protocol in terms of
children’s recovery rate and other standard programme
indicators when compared against international SPHERE
standards(16).
Methods
Location, period and study population
This single-arm proof-of-concept trial was conducted in
Burkina Faso’s Yako Health District. In 2016, Yako had a gen-
eral population of approximately 415 000, with the under-five
population estimated at 82 000, and was served by fifty-four
health centres plus a district hospital. Each health centre was
staffed by a nurse who routinely provided acute malnutrition
treatment. Prevalence of MAM and SAM by WHZ just prior to
implementation of OptiMA was 8·2 % and 1·9 %, respec-
tively(17). Health centre staff were trained on the OptiMA pro-
tocol in November and December 2016. Inclusions for the
study occurred from January through December 2017, and fol-
low-up of study participants ended in March 2018. Children
were considered eligible for enrollment if they were aged
6–59 months with a MUAC < 125 mm or bipedal oedema and
presented to any of the fifty-four outpatient clinics in Yako
District.
Study protocol
Screening for acute malnutrition. A mass community-based
campaign was conducted from June to August 2016 to train
mothers and caretakers throughout Yako District to use
MUAC bracelets and check for oedema in order to screen
their own children for malnutrition. Following the mass
campaign, family MUAC trainings became a routine activity at
all fifty-four health centres and continued to the end of
the study.
Admission/discharge criteria, therapeutic feeding products
and dosage. Table 1 summarises the differences between the
current national protocol and OptiMA, which was implemented
in all of the Yako’s fifty-four health centres for the duration of
the study. Children presenting with MUAC≥ 125mm and
WHZ < −3 were treated in a ‘non-MUAC eligible’ arm according
to the current national protocol.
In contrast to the weight-based RUTF ration in the national
SAM programme, which is fixed at 150–200 kcal/kg per d (628–
837 kJ/kg per d) for the course of treatment, the OptiMA RUTF
ration was calibrated to the child’s degree of wasting based on
the combination of MUAC status and weight. Thus, more nutri-
tional support was given to the most severely malnourished
and then gradually reduced as the child’s MUAC increased.
Children with MUAC < 115 mm or oedema received 175 kcal/
kg per d (732 kJ/kg per d) of RUTF. Children with MUAC
115–119 mm, either at admission or during the course of treat-
ment, received 125 kcal/kg per d (523 kJ/kg per d) of RUTF,
and children with MUAC ≥ 120 mm received 75 kcal/kg per d
(314 kJ/kg per d) of RUTF (with a minimum of one sachet/d)
until discharge from the programme.
Systematic medical treatment. All children underwent
malaria rapid testing upon admission and at any point during
their participation if clinical signs of malaria were detected.
All children with a positive malaria rapid diagnostic test were
prescribed an artemisinin-combination treatment. Amoxicillin
90 mg/kg per d for 7 d was prescribed for all children with
MUAC< 120mm or oedema. Albendazole was given to children
if they had no deworming in the previous 4 months.
Defaulter follow-up
Community health workers traced children who were classified
as defaulters to their caretakers’ homes and completed a
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standardised form recording vital status, MUACmeasure and rea-
sons for defaulting.
Primary and secondary outcomes
The primary outcome was recovery defined as the proportion of
children achieving a MUAC≥ 125mm and absence of oedema
for two consecutive weeks, in good clinical health, with a
minimum programme stay of 4 weeks. Secondary outcomes
were RUTF consumption and other standard programme indica-
tors: death (occurring after programme admission and prior to
recovery), default (being absent for three consecutive visits),
non-response (failure to achieve recovery after 12 weeks in
the programme) and hospitalisations (children referred for
inpatient care at admission or at any point during the course
of treatment).
Data collection procedures and monitoring
One of the five supervisors visited each health facility bimonthly
to ensure protocol adherence and correct completion of patient
records. There was no increase in clinical staff to manage the
nutrition programme.
Data were collected using the national programme individual
outpatient records (modified to include information on family
MUAC-training). These forms were entered into an anonymised
Access database. Data monitoring was conducted from com-
pleted archived patient records and included searching for
each child’s anonymous unique identifier in health centres in
order to ensure that all children enrolled were in the database.
Socio-demographic information on the caretaker and child,
mode of referral, distance to the health centre, caretaker
MUAC-training prior to admission, Amoxicillin prescription
and results of malaria rapid diagnostic test were collected at
the first visit. The child’s weight, MUAC, temperature, clinical
symptoms and amount of RUTF ration were recorded at each
weekly visit. Children’s length was measured at admission and
once a month thereafter. Weight was measured to the nearest
100 g with a Salter scale, and length was measured to the nearest
0·5 cm on a height board with the child in a supine position
(or standing if taller than 85 cm). MUAC was measured to the
nearest mm with a MUAC bracelet demarcated in 1 mm
increments. At each visit, supervisors ensured that scales were
correctly calibrated and MUAC bracelets and height boards were
in good condition.
Data analysis
Data analysis was performed using RStudio software
(RStudio, Inc.).
WHZ, weight-for-age Z-score and height-for-age Z-score
(HAZ) were calculated using WHO 2006 growth standards.
In order to evaluate adherence to the new OptiMA dosage
tables, the difference between weekly RUTF ration provided
to the child and the theoretical OptiMA ration as calculated by
the new tables were described.
Children who were alive but erroneously classified as recov-
ered (after a single MUAC measurement ≥ 125mm) or defaulter
(prior to three consecutive weeks of absence) or non-respondent
(before 12weeks of participation without achieving discharge
criteria), and who did not correspond to another category of exit,
were reclassified as ‘Alive, unconfirmed status’.
Programme outcomes were described overall and stratified
by MUAC category at admission with their 95 % CI and consid-
ered at least as effective as the international SPHERE standards if
the lower limit of the 95 % CI was greater than or equal to the
reference value.
Table 1. Admissions and discharge criteria, treatment products and calculation of dosage in the Burkina Faso national and Optimising treatment for acute
MAlnutrition (OptiMA) protocols*
National protocol OptiMA protocol
SAM MAM Acute malnutrition
Admission MUAC < 115mm or
WHZ <−3 or oedema
MUAC ≥ 115mm and









Super cereal plus 200 g/d




RUTF 125 kcal/kg per d RUTF 75 kcal/kg per d
Calculation
of dosage
According to the weight Fixed amount, regardless
of weight or MUAC
status
According to MUAC status and weight
Discharge
criteria
MUAC ≥ 125mm for two consecutive visits or
WHZ ≥−2 for two consecutive visits
MUAC ≥ 125mm for two consecutive weeks
No oedema minimum
2 weeks
After recovery from SAM:
discharge after 3 months
without losing weight
No oedema for minimum 2weeks
Minimum 4weeks in
programme
Minimum 4weeks in programme
Good clinical health Good clinical health
SAM, severe acute malnutrition; MAM, moderate acute malnutrition; MUAC, mid upper arm circumference; WHZ, weight-for-height Z-score; RUTF, ready-to-use therapeutic food;
RUSF, ready-to-use supplementary food.
* To convert kcal to kJ, multiply by 4·184.
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Multivariable survival analysis to identify variables predictive
of recovery was run using a shared frailty model(18) (extension
of the Cox proportional hazard model), with a random effect
on health centres, and by assuming a Weibull distribution
for the baseline hazard function. A univariate analysis by fitting
a separate model for each covariate was done, variables
having a P-value ≤ 0·2 were entered into multivariate analysis.
P-value < 0·05 was considered as statistically significant in the
final model.
To investigate the contribution of factors that explain the
recovery (i.e. the proportion of recovered children explained
by each variable of interest), adjusted attributable fraction (AF)
of risks was estimated based on the final multivariate model.
The AF for each factor was obtained by the difference between
the predicted number of recovered children in a simulated
dataset where exposure to each variable was removed and
the real number of recovered children in OptiMA database(19).
The adjusted AF were estimated in relation to the recovery at
the median length of stay in the programme. We computed
95 % CI using bootstrapping(19).
Ethics
The present study was approved by the Ethics Committee for
Health Research (2016-6-067) and Technical Review Committee
for Clinical Trial Authorizations (5003720165EC0000) of Burkina
Faso’s Ministry of Health. The trial was registered on
clinicaltrials.gov (NCT03027505). Caregivers gavewritten consent
(signature or fingerprint) prior to enrollment for all children
included in the study. All data were anonymised when entered
into the database, and unique identification numbers were coded.
A data safetymonitoring board conducted an independent interim
analysis, reviewed consolidated results and endorsed completion
of the study.
Results
Of the 5638 children included in the nutrition programme
from January to December 2017, 4958 were included for
analysis (Fig. 1). Children omitted from analysis were those
who relapsed, were readmitted, had missing data, did not meet
OptiMA selection criteria or were not MUAC eligible
(MUAC ≥ 125 mm andWHZ< –3). Non-MUAC eligible children
are described in online Supplementary file 1.
Baseline characteristics of children included under OptiMA
are presented in Table 2. A majority were girls (58·4 %) and
younger than 24 months (82·2 %). Overall, 0·7 % of children
were admitted with oedema, 15·9, 21·6 and 61·8 % with
MUAC< 115, 115–119 and 120–124 mm, respectively. Upon
admission, 71·0 % of children met both MUAC and WHZ
definition for wasting (28·8 % with WHZ <–3, and 42·2 % with
Fig. 1. Flow chart of children admitted under theOptimising treatment for acuteMAlnutrition (OptiMA) protocol, Yako district, Burkina Faso, 2017. MUAC, mid upper arm
circumference; WHZ, weight-for-height Z-score.
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Table 2. Description of children included in Optimising treatment for acute MAlnutrition (OptiMA) protocol, Yako district, Burkina Faso, 2017








n % n % n % n %
Child socio-demographics characteristics
Age (months)
Mean 14·9 12·7 14·5 15·7
SD 8·8 8·4 8·5 8·9
Age category
<24months 4077 82·2 728 88·3 901 84·2 2448 79·9
≥24months 881 17·8 96 11·7 169 15·8 616 20·1
Sex (n 4941)
Male 2057 41·6 326 39·8 421 39·6 1310 42·8
Female 2884 58·4 494 60·2 641 60·4 1749 57·2
Mode of referral (n 4845)
Community agent 1904 39·3 266 33·2 406 38·7 1232 41·2
Mothers screening 628 12·9 154 19·2 158 15·1 316 10·5
Outpatient consultation 2253 46·5 359 44·7 476 45·3 1418 47·4
Inpatient consultation 60 1·2 23 2·9 10 0·9 27 0·9
Distance to the health centre (n 4703)
≥10 km 447 9·5 113 14·4 122 12·0 212 7·3
<10 km 4256 90·5 670 85·6 894 88·0 2692 92·7
Mother’s characteristics at admission
Mother’s status (n 4873)
Alive 4806 98·6 786 97·4 1038 98·2 2982 99·1
Dead 67 1·4 21 2·6 19 1·8 27 0·9
No. of siblings (n 4697)
0 18 0·4 5 0·7 6 0·6 7 0·2
1–4 2711 57·7 433 55·9 595 59·4 1683 57·6
4–12 1968 41·9 336 43·4 400 40·0 1232 42·2
Breast-feeding (n 4512)
Yes 3820 84·7 652 87·7 808 84·3 2360 84·0
No 692 15·3 91 12·3 151 15·7 450 16·0
Years of schooling (n 4442)
No 3941 88·7 672 90·8 855 89·6 2414 87·8
≥1 year 501 11·3 68 9·2 99 10·4 334 12·1
MUAC training (n 4844)
Yes 3733 77·1 614 76·2 772 74·2 2347 78·3
No 1111 22·9 192 23·8 268 25·8 651 21·7
Anthropometric characteristics
MUAC at admission (mm) (n 4922)
Mean 118·7 109·5 116·8 121·7
SD 5·2 5·7 1·5 1·6
WHZ (n 4777)
Mean −2·5 −3·0 −2·6 −2·3
SD 0·9 1·1 0·9 0·9
WHZ categories
<−3 1377 28·8 423 56·3 357 34·6 597 19·9
−3 and −2 2017 42·2 239 31·8 450 43·6 1328 44·3
≥−2 1383 29·0 89 11·9 224 21·7 1070 35·7
HAZ (n 4760)
Mean −1·7 −2·2 −1·8 −1·6
SD 1·4 1·3 1·4 1·3
HAZ categories
<−3 848 17·8 205 27·1 217 21·2 426 14·3
−3 and −2 1150 24·2 216 28·6 253 24·8 681 22·8
≥−2 2762 58·0 335 44·3 552 54·0 1875 62·9
WAZ (n 4772)
Mean −2·8 −3·4 −2·9 −2·5
SD 0·9 0·9 0·8 0·8
WAZ categories
<−3 1858 38·9 496 68·7 494 48·1 868 28·7
−3 and −2 2008 42·1 192 26·6 406 39·5 1410 46·7
≥−2 906 19·0 34 4·7 128 12·4 744 24·6
Malaria data
Malaria RDT (n 4293)
Positive 1103 25·7 192 26·5 275 29·4 636 24·1
Negative 3190 74·3 532 73·5 659 70·6 1999 75·9
Received SMC (n 4907)
Included out of SMC campaign 3550 72·3 615 75·4 785 74·3 2150 70·8
SMC campaign eligible and received 305 6·2 41 5·0 53 5·0 211 6·9
SMC campaign eligible and not received 1052 21·5 160 19·6 218 20·6 674 22·2
MUAC, mid upper arm circumference; WHZ, weight-for-height Z-score; HAZ, height-for-age Z-score; WAZ, weight-for-age Z-score; RDT, rapid diagnostic tests; SMC, seasonal
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WHZ between –3 and –2), while 29·0 % met the MUAC defini-
tion only. Stunting was present in 42·0 % of children. The
proportion and severity of wasting by WHZ, stunting and
underweight were highest among children admitted with
MUAC <115 mm. Most caretakers (77·1 %) received MUAC
training prior to child’s admission.
Fig. 2 shows the difference by visit between the number
of RUTF sachets given to children and the theoretical dosage
per OptiMA protocol. The new dosage regimen was correctly
implemented at all visits for 75·9 % of children. For children
who received a dosage error, the distribution shows that for most
of the visits, the mistake was within two sachets. Mothers who
notified health workers of a planned absence received 2 or
3 weeks of RUTF ration at one visit, whichmay explain the larger
variations.
Overall recovery exceeded the SPHERE standard for both
SAM and MAM programmes: 86·3 % (95 % CI 85·4, 87·2)
(Table 3). Recovery was lowest among children who were most
malnourished at admission, with 70·4 % (95 % CI 67·5, 73·5)
of the children admitted with MUAC< 115mm or oedema
recovering. There were 243 (4·9 %) children who were alive at
discharge but wrongly classified by nurses, with 122 (50·0 %)
of these children erroneously classified as recovered with one
MUAC measure ≥ 125mm instead of two. Mortality rate was
low (0·4 %; 95 % CI 0·0, 1·3), while defaults, non-response and
transfers represented 4·7 % (95 % CI 3·8, 5·6), 3·4 % (95 %
CI 2·5, 4·3) and 0·2 % (95 % CI 0·0, 1·1), respectively.
Table 4 shows programme outcomes stratified by MUAC and
WHZ at admission. Children with both MUAC< 115mm and
WHZ <−3 had the lowest recovery (64·3 %, 95 % CI 60·0,
68·9) and highest non-response (12·5 %, 95 % CI 8·3, 17·1) and
mortality (1·7 %, 95 % CI 0·0, 6·2).
Home visits were conducted for 233 children classified as
defaulters: 113 were alive and physically seen (average MUAC
was 124, SD 7·1), thirty-eight were declared alive by the caretaker
but not physically seen, four were deceased and seventy-eight
could not be found. Among the seventy-seven defaulters with
a MUAC< 115mm at admission, the average number of visits
before default was 4·7 and their last MUAC measure was
115·1mm on average (SD 8·2).
Of 170 non-responders, eighty-four (49·4 %) were admitted
with MUAC< 115 mm and three (1·8 %) for oedema. The aver-
age length of stay and MUAC at last visit for all non-responders
and those with MUAC< 115mm or oedema at admission were
14·6 (SD 3·5) weeks, 120·4 (SD 5·6) mm and 15·3 (SD 3·8) weeks,
119·5 (SD 4·6) mm, respectively.
Of the twenty-two deaths, 72·7 % were younger than
24months, 59·1 % were girls and 54·5 % had a MUAC< 115 or
oedema at admission, while this group accounted for only
16·6 % of all admissions. The average time from admission to
death was 18·8 (SD 19·2) d, with six, eight and eight deaths occur-
ring on the day of admission, 1–21 and 22–60 d after admission,
respectively. Among these sixteen deaths that occurred after the
day of admission, ten children had MUAC< 115mm, nine
were girls and the median age was 14 months (interquartile
range 7·7, 26·2)
Among all recovered children and those admitted with
MUAC< 115mm or oedema, length of stay was 5·8 and
8·1 weeks, MUAC gain was 9·8 and 17·5mm, weight gain was
3·7 and 4·7 g/kg per d and the amount of RUTF provided was
51·0 and 87·4 sachets, respectively (Table 5). The OptiMA
dosage table provided a slightly lower than the anticipated
average daily energetic intake to the most malnourished at
131 kcal/kg per d (548 kJ/kg per d).
Fig. 2. Distribution of the differences by consultation between the number of ready-to-use therapeutic food sachets given to children and the theoretical dosage under
Optimising treatment for acute MAlnutrition protocol, Yako district, Burkina Faso, 2017.
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Table 3. Programme outcome globally and by mid upper arm circumference (MUAC) category at admission among children treated by Optimising treatment for acute MAlnutrition (OptiMA) protocol, Yako
district, Burkina Faso, 2017





MUAC category at admission
Overall (n 4958)
<115mm or oedema (n
824) 115–119 mm (n 1070) 120–124 mm (n 3064)
n % 95 % CI n % 95% CI n % 95% CI n % 95% CI
Exit status
Recovered 75 75 4279 86·3 85·4, 87·2 580 70·4 67·5, 73·5 900 84·1 82·1, 86·2 2799 91·4 90·4, 92·2
Deceased 3 10 22 0·4 0·0, 1·3 12 1·5 0·0, 4·5 6 0·6 0·0, 2·6 4 0·1 0·0, 1·0
Defaulted 15 15 233 4·7 3·8, 5·6 77 9·3 6·4, 12·4 59 5·5 3·6, 7·6 97 3·2 2·2, 4·1
Non-responders 170 3·4 2·5, 4·3 87 10·6 7·6, 13·6 46 4·3 2·3, 6·4 37 1·2 0·2, 2·1
Transferred 11 0·2 0·0, 1·1 4 0·5 0·0, 3·5 1 0·1 0·0, 2·2 6 0·2 0·0, 1·1
Alive: unconfirmed status 243 4·9 4·0, 5·8 64 7·8 4·8, 10·8 58 5·4 0·3, 7·5 121 3·9 3·1, 4·9
Hospitalisation
At least one hospitalisation 680 13·7 12·8, 14·7 269 32·6 29·5, 36·0 186 17·4 15·2, 19·7 225 7·3 6·4, 8·2
Hospital mortality 6 0·9 0·0, 4·0 3 1·1 0·0, 6·5 3 1·6 0·0, 7·7 0
Length of hospital stay (d)
Mean 8·4 9·2 8·2 7·5
SD 5 5·7 4·5 4·2
Table 4. Programme outcomes among children treated with Optimising treatment for acute MAlnutrition (OptiMA) protocol stratified by mid upper arm circumference (MUAC) category and weight-for-height Z-
score (WHZ)* at admission, Yako district, Burkina Faso, 2017
(Numbers and percentages; confidence intervals)
MUAC <115;
WHZ <−3 (n 423)
MUAC <115;
WHZ −3 and −2 (n 239)
MUAC <115;
WHZ ≥ −2 (n 89)
MUAC 115–124;
WHZ < −3 (n 954)
MUAC 115–124;
WHZ −3 and −2 (n 1778)
MUAC 115–124;
WHZ ≥ −2 (n 1294)
n % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% CI n % 95% CI
Recovery 272 64·3 60·0, 68·9 193 80·8 76·6, 85·7 69 77·5 69·7, 85·5 844 84·9 81·2, 89·4 1592 89·5 88·2, 90·9 1176 90·9 89·5, 92·3
Deceased 7 1·7 0·0, 6·2 2 0·8 0·0, 5·7 0 5 0·8 0·0, 5·2 2 0·1 0·0, 1·4 3 0·2 0·0, 1·7
Defaulted 47 11·1 6·8, 15·7 13 5·4 1·2, 10·4 7 7·9 0·0, 15·9 39 5·4 1·7, 9·8 64 3·6 2·3, 4·9 41 3·2 1·8, 4·6
Non-respondent 53 12·5 8·3, 17·1 17 7·1 2·9, 12·1 11 12·4 4·5, 20·4 18 5·4 1·7, 9·8 41 2·3 1·0, 3·6 21 1·6 2·3, 3·1
Transferred 2 0·5 0·0, 5·1 1 0·4 0·0, 5·4 0 3 0·4 0·0, 4·8 1 0·1 0·0, 1·4 2 0·2 0·0, 1·6
Unconfirmed status 42 9·9 5·7, 14·5 13 5·4 1·2, 10·4 2 2·2 0·0 8·0 45 2·9 0·0, 7·3 78 4·4 3·1, 5·7 51 3·9 2·5, 5·4
At least one hospitalisation 151 35·7 31·2, 40·5 67 28·0 22·6, 33·9 14 15·7 8·9, 23·0 121 12·7 10·7, 14·8 175 9·8 8·5, 11·2 89 6·9 5·6, 8·3
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Table 5. Average length of stay, weight gain, mid upper arm circumference (MUAC) gain and average ready-to-use therapeutic food (RUTF) consumption in
recovered children treated with the Optimising treatment for acute MAlnutrition (OptiMA) protocol, Yako district, Burkina Faso, 2017




(n 580) 115–119 (n 900) 120–124 (n 2799)
Mean SD Mean SD Mean SD Mean SD
Average time to recovery (week) 5·8 2·5 8·1 3·4 6·5 2·7 5·2 1·9
Average MUAC gain (mm) 9·8 5·1 17·5 5·4 11·2 3·2 7·7 3·7
Average weight gain (g/kg per d) 3·7 2·2 4·7 2·5 3·8 1·9 3·5 2·2
Average no. of RUTF 58·9 24·9 86·4 34·4 66·1 24·4 50·9 16·7
Median no. of RUTF 51 79 59 46
IQR 42–68 63–104 49–76 40–57
Consumption (kcal/kg per d)* 106 26·8 131·1 33·3 112 26·5 98·8 21·3
* To convert kcal to kJ, multiply by 4·184.
Table 6. Factors associated and attributable fraction (AF) with nutritional recovery (n 4163) among all children (n 4958) included in Optimising treatment for
acute MAlnutrition (OptiMA) protocol, Yako district, Burkina Faso, 2017*
(Numbers and percentages; hazard ratios (HR) and 95% confidence intervals)
n/N %
Univariate analysis Multivariate analysis (n 4201) AF
Crude
HR 95% CI P
Adjusted
HR 95% CI P AF 95% CI
Child socio-demographic characteristics
Age category (n 4958)
<24months 3376/4077 82·8 1 1 <0·0001
≥24months 787/881 89·3 1·61 1·48, 1·75 1·61 1·48, 1·75 9·7 8·4, 13·1
Sex (n 4941)
Female 2381/2884 82·6 1 <0·0001 1 <0·0001
Male 1768/2057 86 1·21 1·14, 1·29 1·21 1·13, 1·29 8·1 4·0, 10·4
Mode of referral (n 4845)
Outpatient consultation 1869/2253 83 1 0·05
Community agent 1619/1904 85 1·04 0·97, 1·11
Mothers screening 545/628 86·8 0·9 0·81, 1·01
Inpatient consultation 49/60 81·7 1·15 0·86 , 1·53
Distance to the health centre (km) (n 4703)
≥10 376/447 84·1 1 <0·0001 1 <0·001
<10 3585/4256 84·2 1·28 1·13, 1·45 1·25 1·11, 1·42 18·1 11·0, 24·8
Mother’s characteristics at admission
Mother’s status (n 4873)
Death 53/67 79·1 1 0·04 1 0·03
Alive 4047/4806 84·2 1·36 1·02, 1·81 1·39 1·02, 1·89 26·9 9·5, 40·8
No. of siblings (n 4697)
0 13/18 72·2 1 0·9
1–4 2267/2711 83·6 0·97 0·57, 1·63
4–12 1683/1968 85·5 0·98 0·58, 1·66
Breast-feeding (n 4512)
No 597/692 86·3 1 <0·0001
Yes 3226/3820 84·5 0·76 0·70, 0·83
MUAC training
No 881/1111 79·3 1 0·02 1 0·05
Yes 3201/3733 85·7 1·10 1·01, 1·20 1·09 1·0, 1·19 6·7 1·8, 12·0
Malaria prevention
At least one RDT positive
Yes 1160/1354 85·7 1 0·2
No 2916/3504 83·2 1·05 0·98, 1·13
SMC† at admission
Included out of SMC campaign‡ 2998/3350 84·5 1 0·002 1 0·001
SMC campaign‡ eligible and received 258/305 84·6 1·09 0·96, 1·25 1·06 0·93, 1·22 6·6‡ 2·5, 12·7
SMC campaign‡ eligible and not
received
872/1052 82·9 0·89 0·82, 0·96 0·87 0·81, 0·94
MUAC, mid upper arm circumference; RDT, rapid diagnostic tests; SMC, seasonal malaria chemoprevention.
* Shared frailty model with a random effect on health centres censoring at 12 weeks of inclusion in the programme.
† SMC campaign period from July to October 2017.
‡ SMC at admission was combined in two categories ‘included out of SMC campaign’ and ‘included during SMC campaign’, the reference chosen for the AF calculation was ‘included
during SMC campaign’.
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UNICEF Burkina Faso plans an average of 140 sachets per
SAM child treated. The comparable group in OptiMA is the
1778 children who met standard SAM admission criteria and
whose average RUTF ration was reduced by nearly half at
72·2 sachets per child treated. The 3072 children treated under
OptiMA who fit the current MAM case definition consumed an
average of 54·3 RUTF sachets/child which is lower than the
60–90 ready-to-use supplementary food sachets/child typically
planned for MAM programming.
Table 6 shows factors associated with recovery after control-
ling for age and sex: alive mother status (adjusted hazard ratio
1·39; 95 % CI 1·02, 1·89), child of a caretaker who received
MUAC training (adjusted hazard ratio 1·09; 95 % CI 1·01,
1·19) and who lived close to health centres (adjusted hazard
ratio 1·25; 95 % CI 1·11, 1·42) were more likely to recover.
Conversely, children who did not receive seasonal malaria
chemoprevention during July and October were less likely to
recover (0·87; 95 % CI 0·81, 0·94).
Globally, AF indicate that 57·1 % (95 % CI 46·5, 69·6) of the
recovery was explained by the six variables selected in the final
model. The two variables that explain most of the recovery
are: children whose mother is alive (AF 28·9 % (95 % CI 9·5,
40·8) and living within 10 km of the health centre (18·1 %,
95 % CI 11·0, 24·8).
Discussion
This proof-of-concept trial evaluated a therapeutic nutrition
protocol for children affected by acute malnutrition, defined
as MUAC< 125 mm or oedema, and treated with one product
(RUTF) at a gradually reduced dose based on a child’s weight
and MUAC status. The OptiMA protocol was implemented in a
‘real-life’ setting by Burkinabe Ministry of Health personnel in
all fifty-four health centres of Yako District, with operational
support from a national and international non-governmental
consortium and an established UNICEF-supported RUTF supply
chain. Nurses had minimal difficulty adapting to this new
protocol as evidenced by excellent adherence to the new dosing
table and application of the new admission criteria. Programme
outcomes overall were satisfactory with substantial reduction in
RUTF ration compared with standard SAM treatment. However,
recovery and non-response rates were unsatisfactory in children
admitted at MUAC< 115mm or oedema.
Overall recovery and mortality rates reported here, 86·3 and
0·4 % respectively, compare favourably to the 83 % recovery and
4 % mortality reported by a similar MUAC-based study in Sierra
Leone, which had a more rapid reduction in RUTF dosage than
OptiMA(11). A MUAC-based programme previously imple-
mented in the same district of Burkina Faso and using
MUAC< 120mm for admissions reported 91·6 % recovery and
1·1 % mortality, but the present study did not use a reduced
RUTF regimen and had a less stringent discharge criterion of a
single measure of MUAC≥ 124mm(6).
Recovery in the category of children admitted at
MUAC< 115mm or oedema (70·4 %) was poorer than antici-
pated; this was largely attributable to high non-response
(10·6 %) and defaulter rates (9·3 %). Non-responders and
defaulters did achieve an average MUAC of 119·5 and
115·1mm at exit, respectively, while the average MUAC at
admission in the MUAC< 115 mm group was 109·5 mm.
Mortality remained low at 1·5 % and is similar to themortality rate
of 1·6 % reported for childrenwithMUAC< 115mmat admission
in the prior MUAC-based programme in this same district(6).
Elsewhere among MUAC-based programmes without RUTF
reduction, recovery rates for this category have ranged from
57·4 % in India, 63·4 % in Malawi and 82 % in Sudan(20–22). In
the MUAC-based programme with RUTF dose reduction in
Sierra Leone recovery for this sub-group was 75·3 %(23); how-
ever, nutritional oedema was more prevalent in Sierra Leone
(2·9 v. 0·7 % in OptiMA). This range of reported recovery rates
with and without RUTF dose reduction suggests that recovery
for this category is challenging. Other important factors like
underlying disease (HIV, tuberculosis, sickle cell disease) might
have contributed to a low recovery rate.
Similarly, recovery rate was the lowest (64·3 %) for children
admitted with MUAC< 115mm and WHZ < –3 (8·8 % of all
admissions) and is again driven primarily by a high non-
response rate at 12·5 %. Stunting was also highly prevalent in this
group, reaching 57·9 %. Previous studies described a correlation
between shorter length and treatment non-response rate,
suggesting that severely wasted and stunted children may
require other interventions over a longer time period to improve
growth trajectory(7,24).
The sub-optimal outcomes for the small proportion of
severely wasted and stunted children should be interpreted in
light of overall programme performance. Under OptiMA, only
16 % of children treated were admitted with MUAC< 115mm
or oedema, while 84 % were admitted with MUAC between
115 and 124mm, whereas the proportion of children in each cat-
egory in the Sierra Leone study was 30 and 70 %(11). This might
suggest that the OptiMA programme achieved good coverage
and caught most children early in the wasting process. Thus,
those children who exhibit severe wasting and stunting, in spite
of apparently good access to treatment, may represent either a
history of low birth weight or malnutrition secondary to chronic
illness, both of which lower expectations for treatment
outcomes.
Current SAM programmes typically plan RUTF consumption
between 120 and 150 sachets per child treated, while MAM pro-
grammes plan between sixty and ninety sachets of ready-to-use
supplementary food per child(25,26). However, comparisons of
average rations must consider variations in discharge criteria.
Under OptiMA, discharge was stringent: two consecutives
measures of MUAC≥ 125mm. In this light, the overall RUTF
consumption of 60·8 sachets average per child per course of
treatment is highly encouraging. However, further study will
be needed to determine if increasing RUTF dosage for children
admitted with MUAC< 115mm will improve recovery and non-
response even if other factors appear to influence recovery rate
as shown in the multivariate analysis.
Female sex bias in MUAC-based nutrition programmes has
been documented in previous studies(11,27), similar to what the
present study observed with 58·4 % of girls at admission.
Isanaka et al. also clearly show that WHZ score preferentially








bridge.org/core . IP address: 109.215.81.160 , on 19 Jan 2021 at 15:33:38 , subject to the Cam
bridge Core term






selects males(27). Thus combining anthropometric criteria, MUAC
and WHZ serve to maintain sex balance in nutrition pro-
grammes. Using MUAC as the single anthropometric criterion
for programme admission may require improving MUAC sensi-
tivity for boys and specificity for girls.
The multivariable survival model highlighted that recovery
was positively associated with male children older than 24 m,
living within 10 km of the health facility, whose mother was
alive and had been trained to use MUAC. Recovery was nega-
tively associated with children who had not received seasonal
malaria chemoprevention between July and October. Most of
these results have already been found in other studies. It is well
known that female and younger children present lower
MUAC(28). As for distance to the health facility, a study from
Ethiopia showed that SAM children living within 25 min of
the facility were 1·53 times more likely to recover(29). It has also
been shown that mothers screening their children by MUAC
can lead to earlier initiation of care(12). The low proportion of
self-referral by mothers (12·9 %) is likely due to an underesti-
mation because many mothers sought confirmation from a
Community Health Worker (CHW) after using MUAC at
home and then reported being referred by a CHW at
admission. To the best of our knowledge, it is the first time that
a positive association is demonstrated between training mother
to use MUAC bracelet and recovery, likely due to a better
care-seeking behaviour resulting from such trainings. The neg-
ative association between children who did not receive CPS
should be viewed with caution because the reason why these
children did not receive the seasonal malaria chemoprevention
was unknown and we cannot exclude a confusion bias or even
reverse causality. Of these six variables associated with recov-
ery, AF calculation highlighted, unsurprisingly, that recovery
was primarily driven by maternal vital status and living within
10 km of the health facility.
The main limitation in the present study is the absence of a
comparator group. In order to determine how MUAC-based
integrated SAM and MAM protocols perform compared with
current protocols that rely onMUAC andWHZ criteria, additional
randomised trials, in multiple contexts, are necessary. Another
limitation is that we did not collect data on possible RUTF
sharing. But, it was previously shown in a study on MAM
treatment in the same location that nearly two-thirds of children
consumed all of the prescribed LNS ration themselves(30).
Lastly, this analysis relied on routinely collected programme
data. Extensive data monitoring was carried out throughout
the study to ensure that all children found in health centre
registers were retrieved in the OptiMA database. To our
knowledge, such monitoring is rarely performed in program-
matic studies. The strength of the present study is that it shows
it is possible to conduct robust data monitoring in a ‘real-life’
programme to generate a high-quality individualised database.
However, it was not without challenge. The reclassification of
children erroneously categorised at exit-influenced OptiMA’s
recovery rate downwards. Adherence to routine amoxicillin
prescription for children with MUAC < 120 mm or oedema as
specified in the protocol was uneven and thus precluded
any analysis of correlation between this prescription and
recovery.
Conclusion
A simplified, combined SAM and MAM protocol based on early
detection through household MUAC screenings, treatment with
one product determined by the presence of oedema and/or
MUAC< 125mm, and progressive RUTF dose reduction had
programme outcomes that exceeded national Burkina Faso
and international SPHERE standards. This early detection and
treatment initiation with progressively reduced RUTF ration
shows promise and warrants further operational pilots in differ-
ent contexts. However, randomised control trials are needed to
compare the strategy to current national protocols(31). Because of
low recovery among children admitted with MUAC< 115mm,
further study is also needed to determine whether increasing
RUTF dosage for the most severely malnourished will improve
outcomes.
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